Inhibrx Biosciences Statistics
Share Statistics
Inhibrx Biosciences has 14.48M shares outstanding. The number of shares has increased by -69.39% in one year.
| Shares Outstanding | 14.48M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.94M |
| Failed to Deliver (FTD) Shares | 857 |
| FTD / Avg. Volume | 1.05% |
Short Selling Information
The latest short interest is 895.66K, so 6.19% of the outstanding shares have been sold short.
| Short Interest | 895.66K |
| Short % of Shares Out | 6.19% |
| Short % of Float | 8.96% |
| Short Ratio (days to cover) | 14.06 |
Valuation Ratios
The PE ratio is -7.42 and the forward PE ratio is -1.5.
| PE Ratio | -7.42 |
| Forward PE | -1.5 |
| PS Ratio | 994.97 |
| Forward PS | 106 |
| PB Ratio | 41.17 |
| P/FCF Ratio | -9.05 |
| PEG Ratio | n/a |
Enterprise Valuation
Inhibrx Biosciences Inc. has an Enterprise Value (EV) of 1.72B.
| EV / Earnings | -7.14 |
| EV / Sales | 957.31 |
| EV / EBITDA | -8.34 |
| EV / EBIT | -7.86 |
| EV / FCF | -8.71 |
Financial Position
The company has a current ratio of 5.25, with a Debt / Equity ratio of 4.8.
| Current Ratio | 5.25 |
| Quick Ratio | 5.45 |
| Debt / Equity | 4.8 |
| Total Debt / Capitalization | 82.77 |
| Cash Flow / Debt | -0.92 |
| Interest Coverage | -6.89 |
Financial Efficiency
Return on equity (ROE) is -5.55% and return on capital (ROIC) is -86.43%.
| Return on Equity (ROE) | -5.55% |
| Return on Assets (ROA) | -0.78% |
| Return on Capital (ROIC) | -86.43% |
| Revenue Per Employee | 10.84K |
| Profits Per Employee | -1.45M |
| Employee Count | 166 |
| Asset Turnover | 0.01 |
| Inventory Turnover | -0.1 |
Taxes
| Income Tax | 3.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -48.06% in the last 52 weeks. The beta is 2.88, so Inhibrx Biosciences 's price volatility has been higher than the market average.
| Beta | 2.88 |
| 52-Week Price Change | -48.06% |
| 50-Day Moving Average | 15.36 |
| 200-Day Moving Average | 21.09 |
| Relative Strength Index (RSI) | 44.33 |
| Average Volume (20 Days) | 81.47K |
Income Statement
In the last 12 months, Inhibrx Biosciences had revenue of $1.80M and earned -$241.36M in profits. Earnings per share was $-5.12.
| Revenue | 1.80M |
| Gross Profit | 609.00K |
| Operating Income | -219.22M |
| Net Income | -241.36M |
| EBITDA | -206.69M |
| EBIT | -219.22M |
| Earnings Per Share (EPS) | -5.12 |
Balance Sheet
The company has $277.92M in cash and $210.14M in debt, giving a net cash position of $67.78M.
| Cash & Cash Equivalents | 277.92M |
| Total Debt | 210.14M |
| Net Cash | 67.78M |
| Retained Earnings | -613.73M |
| Total Assets | 222.56M |
| Working Capital | 163.35M |
Cash Flow
In the last 12 months, operating cash flow was -$193.31M and capital expenditures -$4.59M, giving a free cash flow of -$197.90M.
| Operating Cash Flow | -193.31M |
| Capital Expenditures | -4.59M |
| Free Cash Flow | -197.90M |
| FCF Per Share | -4.2 |
Margins
Gross margin is 33.83%, with operating and profit margins of -12.18K% and -13.41K%.
| Gross Margin | 33.83% |
| Operating Margin | -12.18K% |
| Pretax Margin | -13.32K% |
| Profit Margin | -13.41K% |
| EBITDA Margin | -11.48K% |
| EBIT Margin | -12.18K% |
| FCF Margin | -10.99K% |
Dividends & Yields
INBX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -35.04% |
| FCF Yield | -93.57% |
Analyst Forecast
The average price target for INBX is $27, which is 84.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $27 |
| Price Target Difference | 84.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 27.95 |
| Piotroski F-Score | 6 |